엑셀세라퓨틱스, '中 샹야'와 5억 규모 엑소좀 배지 공급 계약 체결

본 내용은 당사가 지난 3월 25일 중국 샹야와 엑소좀 전용 배지 계약 체결과 관련하여 ′더바이오′에 2026.03.20 게재된 영문 기사입니다. 

- Shinya Biomedicine names Nobel Laureate Martin John Evans as CTO

- Full-scale entry into China’s KRW 20 trillion ‘exosome’ R&D market

 

[by Kang, In Hyo] Xcell Therapeutics, a company specializing in culture media for cell and gene therapy (CGT), announced on March 25 that it has entered into a supply agreement for ‘exosome media’ with Shinya Biomedicine (hereinafter referred to as Shinya), a Chinese advanced regenerative medicine company. This agreement is viewed as a signal for Xcell Therapeutics′ full-scale expansion into overseas markets, particularly within the exosome sector, which has emerged as a high-growth global industry.

The agreement was signed on March 24 at the headquarters of Xcell Therapeutics in Gangnam District, Seoul, in the presence of key executives from both companies, including Liu Yang, General Managerof Shinya and Lee Uri, CEO of Xcell Therapeutics. Under the terms of the agreement, Xcell Therapeutics will supply its exosome culture medium,‘CellCor EXO CD,’ valued at around USD 350,000 (approximately KRW 520 million), with the contract period extending through March 2027.

Shinya is a high-end, research and development (R&D)-focused biotechnology company in which Sir Martin John Evans, a Nobel Laureate in Physiology or Medicine, serves as Chief Technology Officer (CTO). Evans is a world-renowned scholar who was awarded the Nobel Prize in Physiology or Medicine in 2007 for his pioneering work in establishing gene targeting technology using embryonic stem cells. He is also a Fellow of the Royal Society (FRS) and a founding member of the UK Academy of Medical Sciences.

Shinya focuses on the R&D and industrialization of third-generation recombinant collagen-based biomaterials, achieving notable progress in areas of wound healing and medical aesthetics. More recently, the company has been accelerating efforts to secure next-generation growth drivers by expanding investments into advanced regenerative medicine sectors, including stem cell therapies and exosomes. Headquartered in Huzhou, Zhejiang Province, China, Shinya operates research and development centers and manufacturing facilities covering approximately 10,000 square meters.

China is actively promoting the fields of stem cells, gene technologies, and exosomes as ‘national strategic industries,’accompanied by sustained large-scale investment. Exosomes, in particular, are being utilized as biomaterials in various industries, including therapeutics, diagnostics, and medical aesthetics, and are experiencing rapid expansion, especially alongside the surging growth of the medical beauty market. With an average annual growth rate exceeding 30%, the exosome segment is regarded as one of the fastest-growing areas within the biopharmaceutical industry. According to global market analyses, the sector is projected to reach approximately KRW 20 trillion by the mid-2030s, with China positioned as a key driver of this expansion.

"Xcell Therapeutics′ chemically defined culture medium enhances both exosome production efficiency and operational convenience. Its strong cell proliferation capacity enables the harvesting of exosomes without the need for medium replacement during the process, representing a significant advantage. We have confirmed its potential to serve as a new ′game changer′ in China’s exosome R&D market," remarked Liu Yang, General Manager of Shinya.

“This agreement with Shinya, where R&D is led by a Nobel laureate, demonstrates both the global technological competitiveness and commercial value of our chemically defined culture media,” said Lee Uri, CEO of Xcell Therapeutics. “Building on this supply contract, we plan to gradually expand the scope of collaboration and supply scale to accelerate our entry into global markets, including China,” he added.

출처 : 더바이오(https://www.thebionews.net)